Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

VANCOUVER, July 16 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Long Paclitaxel-Eluting Coronary Stent System, a next-generation drug-eluting stent (DES) designed for long lesions. At 38 mm, it is the longest available DES, providing doctors an option that can potentially reduce the number of stents used in more complex cases, simplifying procedures and reducing costs. It affords a more efficient treatment option for the estimated 8 to 10 percent(1) of patients with long lesions. Boston Scientific plans to launch the product in the U.S. next month. It received CE Mark approval in 2007.

"The TAXUS Liberte Long Stent offers physicians and patients distinct advantages compared to using two overlapping drug-eluting stents," said Mark Turco, M.D., FACC, FSCAI, Director of the Center for Cardiac Vascular Research at Washington Adventist Hospital, Takoma Park, Maryland. "In the ATLAS Long Lesion Trial, the 38 mm TAXUS Liberte Stent significantly reduced myocardial infarction when compared to the TAXUS(R) Express(R) Stent, making the TAXUS Liberte Long Stent an attractive option for interventional cardiologists faced with long, challenging lesions."

The TAXUS ATLAS Long Lesion Trial reported a significant 79 percent reduction in the rate of nine-month myocardial infarction for the TAXUS Liberte Long Stent as compared to the TAXUS Express Stent control (1.3% vs. 6.3%, p=0.026). At two years, the composite measure of cardiac death or myocardial infarction showed a significant 63 percent reduction for the TAXUS Liberte Long Stent compared to
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Calif. , Sept. 30, 2014 FemCap ... women,s health announces its receipt of a patent No: ... menstrual cup has also received FDA clearance in the ... and the CE in Europe. This patent is related to ... with this issuance, the company is releasing FemmyCycle Teen, ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Lyme ... funder of Lyme disease research at universities, today announced ... focused on the identification, treatment and cure for Lyme ... had received the most applications in its history—over 20 ... , “While we were pleased to receive so many ...
(Date:9/30/2014)... UFP Technologies, a producer of ... recently introduced a custom insulated shipping container to ... new insulated shipper solves the issue of temperature ... Technologies’ BioShell is a universal storage container which ... and shipping. The insulated shipper keeps frozen BioShells ...
(Date:9/29/2014)... Each year in the US, ... attention. In the military, burn injury is a ... medical care. More than 800 service members sustained ... heal slowly, remain inflamed and often become infected, ... and functionally damaging. While developments in supportive care ...
Breaking Biology Technology:The FemmyCycle 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3Faster Healing with Fewer Scars 2
... , ... ... ... ...
... ... with a Complete, Cloud-Enabled API for Developers , ... Westborough, Mass. (Vocus) March 4, 2010 -- This seminar details the fast-growing ... The free seminar will include lunch, discussion, and startup to Free Basic Account. , ...
... ... ... ... ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 2OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 3GenomeQuest Hosting Seminar at X Gen Congress In San Diego 2GenomeQuest Hosting Seminar at X Gen Congress In San Diego 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 28Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 29Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 30Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 31Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 32
(Date:9/30/2014)... Having trouble getting pregnanteven with IVF? Here,s some hope: ... of The FASEB Journal , explains ... protein known as PAWP, which induced embryo development in ... of embryo development by the sperm cell during fertilization. ... represent a major paradigm shift in our understanding of ...
(Date:9/30/2014)... a suite of perilous threats in today,s ocean. ... climate change, fragile coral ecosystems are disappearing at ... some species of corals surrounding the island of ... in their tropical environment: coral guard-crabs. New research ... Marine Station scientist Seabird McKeon and the museum,s ...
(Date:9/29/2014)... species of gut bacteria called Clostridium ramosum , coupled ... The work is published this week in mBio , ... , A research team from the German Institute of ... gut bacteria including C. ramosum gained weight when ... C. ramosum were less obese even when consuming a ...
Breaking Biology News(10 mins):Synthetic sperm protein raises the chance for successful in vitro fertilization 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2
... varies dramatically according to whether the nurses leave the ... airflow in a "Nightingale" warda classic hospital ward design ... bedsby using tracer gases to simulate how airborne infections ... generally good when windows were left open, keeping the ...
... Male circumcision reduces the abundance of bacteria living on the ... protection against HIV, according to a study led by the ... a significant shift in the bacterial community or microbiome of ... online journal mBio . This international collaboration focused ...
... What do woolly mammoths wandering around the ancient ... do with predicting how species could respond to ... Maryland Center for Environmental Science,s Appalachian Laboratory, along ... the University of California-Merced, have received a three-year, ...
Cached Biology News:Energy efficiency could increase infection risks in hospital wards 2Energy efficiency could increase infection risks in hospital wards 3TGen-led study discovers dramatic changes in bacteria following male circumcision 2Scientists look to ancient past to better predict how species may respond climate change 2
SHEEP ANTI FLECAINIDE...
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
... are ideal for use in refrigerators, freezers, or liquid ... vibrant colors allow for color coding to project, user, ... drainage or promote cool air circulation. Supplied with 10 ... tubes. Box dimensions: 13 x 13 x ...
RABBIT ANTI BACTERIAL HISTIDASE...
Biology Products: